Medifuture Pharmaceuticals Private Limited
About Medifuture Pharmaceuticals Private Limited
Data last updated:
Medifuture Pharmaceuticals Private Limited is a private limited company based in Delhi, India. It operates in the ayurvedic products and services segment of the healthcare sector. It was incorporated on 02 June 2009 and has been in existence for over 17 years.
The company is registered with the Registrar of Companies (ROC), Delhi, under CIN U36103DL2009PTC190810. Its GSTIN is 07AAKCA0038M1ZN (Delhi). The company holds 2 GST registrations, all of them active.
The company has an authorised share capital of ₹50 Lakh and a paid-up capital of ₹15 Lakh. It is led by directors Shashi Setia and Aastha Setia.
Its last annual general meeting (AGM) was held on 23 September 2025, and its latest financial statements are for the year ended 31 March 2025. The registered office is at Unit No. 206 Tower – A Nextra The Address, Plot No. 4B District Centre Mayur Vihar Phase – 1 Extension, Delhi, India – 110091.
As per the financials filed for FY 2025, the company reported a revenue of ₹30.78 Cr, a decline of 49% compared to the previous year. For the same year it recorded a net profit of ₹1.33 Cr (net margin 4.3%) and EBITDA of ₹1.87 Cr (EBITDA margin 6.1%). Revenue has grown at a compounded annual rate (CAGR) of 707% over three years and 412% over five years.
The current compliance status is marked as compliant by the Registrar of Companies.
Company details
Contact details
Medifuture Pharmaceuticals Private Limited's registered office is in Delhi, Delhi. Its e-mail address and telephone number are in the company report.
- Email
- Telephone
- Registered AddressUnit No. 206 Tower – A Nextra The Address, Plot No. 4B District Centre Mayur Vihar Phase – 1 Extension, Delhi, India – 110091
- IndustryHealthcare, Ayurvedic Products & Services
To see the full contact details of Medifuture Pharmaceuticals Private Limited, buy the company report.
- Company details, directors and signatories
- Historical financials and ratios
- Shareholding pattern and group structure
- Charges with holder and property details
- Legal cases, compliance and MCA filings
Business activity
The main business activities of Medifuture Pharmaceuticals are trade and professional, scientific and technical. In detail, this covers wholesale trading and other professional, scientific and technical activities. 2 activity segments are registered with the MCA.
| Main activity group code | Main activity | Business activity code | Business activity | Share of turnover |
|---|---|---|---|---|
| G | Trade | G1 | Wholesale Trading | |
| M | Professional, Scientific and Technical | M9 | Other professional, scientific and technical activities |
To see the full business activity and turnover split of Medifuture Pharmaceuticals Private Limited, buy the company report.
Financials of Medifuture Pharmaceuticals Private Limited
FY 2025 filings availableMedifuture Pharmaceuticals Private Limited reported revenue of ₹30.78 Cr (down 49% YoY) for FY 2025.
Compounded Annual Growth Rate (CAGR)
Revenue fell 49% in the latest year, but over five years it has grown at a compounded annual rate (CAGR) of 412%. EBITDA fell 52% in the latest year. Three- and five-year figures are compounded annual growth rates (CAGR): the steady yearly rate that links the first and the last year. All are worked out from the filed statements.
Financial Statement Summary
| Metrics | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 |
|---|---|---|---|---|---|
| Profit and Loss Statement | |||||
| Revenue from Operations | |||||
| Other Income | |||||
| Total Revenue | |||||
| Cost of Materials Consumed | |||||
| Employee Benefit Expense | |||||
| Finance Costs | |||||
| Depreciation and Amortisation | |||||
| Other Expenses | |||||
| Total Expenses | |||||
| EBITDA | ₹1.87 Cr | ||||
| Profit Before Tax | |||||
| Tax Expense | |||||
| Net Profit (PAT) | ₹1.33 Cr | ||||
| Balance Sheet | |||||
| Share Capital | |||||
| Reserves and Surplus | |||||
| Net Worth (Total Equity) | |||||
| Long-term Borrowings | |||||
| Short-term Borrowings | |||||
| Trade Payables | |||||
| Total Liabilities | |||||
| Fixed Assets | |||||
| Investments | |||||
| Inventories | |||||
| Trade Receivables | |||||
| Cash and Bank Balance | |||||
| Total Assets | |||||
Financial Ratios
| Metrics | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 |
|---|---|---|---|---|---|
| Profitability | |||||
| EBITDA Margin | 6.1% | ||||
| Net Profit Margin | 4.3% | ||||
| Return on Equity (ROE) | |||||
| Return on Capital Employed (ROCE) | |||||
| Return on Assets (ROA) | |||||
| Liquidity and Debt | |||||
| Current Ratio | |||||
| Quick Ratio | |||||
| Debt-to-Equity Ratio | |||||
| Interest Coverage Ratio | |||||
| Efficiency and Growth | |||||
| Asset Turnover | |||||
| Receivable Days | |||||
| Payable Days | |||||
| Inventory Days | |||||
| Revenue Growth | |||||
| Net Profit Growth | |||||
To see the full financial statements and ratios of Medifuture Pharmaceuticals Private Limited, buy the company report.
Board of directors of Medifuture Pharmaceuticals Private Limited
Medifuture Pharmaceuticals has 2 current directors and 8 former directors. Current directors are listed first, with their designation and appointment date.
| Name | Designation | Appointment Date | Tenure | Status |
|---|---|---|---|---|
| Shashi Setia | Director | 16 Aug 2018 | 8 Years 2 Months | Current |
| Aastha Setia | Director | 25 Oct 2021 | 5 Years 0 Months | Current |
Auditor
Medifuture Pharmaceuticals Private Limited is audited by SUNIL ANIL & ASSOCIATES for the financial year 2023.
| Auditor firm | Financial year | Firm registration number |
|---|---|---|
| SUNIL ANIL & ASSOCIATES | FY 2023 | 007464N |
Shareholding
The shareholding of Medifuture Pharmaceuticals Private Limited is on record for 5 financial years, the latest being FY 2023, split between promoters, domestic institutions, foreign institutions, public shareholders and others.
| Shareholder category | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|---|---|
| Promoters | |||||
| Domestic institutional investors (DII) | |||||
| Foreign institutional investors (FII) | |||||
| Public | |||||
| Others |
To see the full shareholding pattern of Medifuture Pharmaceuticals Private Limited, buy the company report.
Legal cases
No court or tribunal cases involving Medifuture Pharmaceuticals Private Limited are on our record; a case search with case numbers, parties and status is in the company report Buy the company report.
MSME payment delays
No delayed payments to MSME suppliers are on our record for Medifuture Pharmaceuticals Private Limited; the supplier-wise MSME Form 1 check is in the company report Buy the company report.
GST
Medifuture Pharmaceuticals has 2 GST registrations: 2 active.
| GSTIN | State | Status | Registered on |
|---|---|---|---|
| 07AAKCA0038M1ZN | Delhi | Active | 13 Jan 2022 |
| 09AAKCA0038M1ZJ | Uttar Pradesh | Active | 23 Sep 2022 |
To see the full GST registrations and return filing status of Medifuture Pharmaceuticals Private Limited, buy the company report.
Recent activity
Medifuture Pharmaceuticals Private Limited has 10 board changes on record since 2014: 2 appointments and 8 cessations. The latest: Aastha Setia ceased to be Additional Director on 30 Sep 2022.
1 earlier event is in the company report.
Frequently asked questions
Medifuture Pharmaceuticals is an active private limited company based in Delhi, India. The company works in ayurvedic products and services, within the healthcare industry. It was incorporated on 02 June 2009 (17+ years old) and is registered under CIN U36103DL2009PTC190810.
Medifuture Pharmaceuticals has 2 current directors:
- Shashi Setia - Director
- Aastha Setia - Director
The latest financial statements of Medifuture Pharmaceuticals on record with the MCA are for the year ended 31 March 2025. Its last annual general meeting was held on 23 September 2025. Year-wise statements from 2015 are in the company report.
The GSTIN of Medifuture Pharmaceuticals is 07AAKCA0038M1ZN, registered in Delhi. The company has 2 GST registrations in all, of which 2 are active. Other active GSTINs include 09AAKCA0038M1ZJ (Uttar Pradesh).
The CIN (Corporate Identification Number) of Medifuture Pharmaceuticals is U36103DL2009PTC190810. It is issued by the Ministry of Corporate Affairs under the Companies Act, 2013, and uniquely identifies the company in India.
Medifuture Pharmaceuticals was incorporated on 02 June 2009, making it 17+ years old. It is registered with the Registrar of Companies, Delhi.
Aastha Setia ceased to be Additional Director on 30 Sep 2022. Aastha Setia was appointed as Director on 25 Oct 2021. Mahasweta Sahoo ceased to be Additional Director on 31 Dec 2020. Medifuture Pharmaceuticals has 10 board changes on record in total.
The registered office of Medifuture Pharmaceuticals is at Unit No. 206 Tower – A Nextra The Address, Plot No. 4B District Centre Mayur Vihar Phase – 1 Extension, Delhi, India – 110091.
Medifuture Pharmaceuticals operates in the healthcare industry, in the ayurvedic products and services segment.
The compliance status of Medifuture Pharmaceuticals is compliant as of 07 August 2026. The company is actively filing with the Registrar of Companies.
Sample company reports
The same report you get when you buy one: financials, directors, ownership, deals, charges, legal cases, brands and filings, with the Excel workbook alongside.
